Regeneron Pharmaceuticals, Inc.'s Stock Analysis

Regeneron Projects $127 Million Charge Impacting Earnings in 2026

Regeneron Pharmaceuticals anticipates a charge of approximately $127 million related to acquired in-process research and development (IPR&D) for the second quarter of 2026. This charge is expected to negatively affect both GAAP and non-GAAP net income per diluted share by around $1.00, stemming from up-front and opt-in payments associated with collaboration and licensing agreements. The final results for this period remain subject to the company’s financial closing procedures, and actual results may differ from these preliminary estimates.

The company also notes that its non-GAAP financial measures, which exclude certain non-cash items, are intended to provide investors with a clearer view of its operational performance. However, these measures have limitations as they exclude recurring expenses and may not be comparable with similar metrics from other companies. Regeneron emphasizes that any non-GAAP measure should be considered an addition to, rather than a replacement for, GAAP financial performance metrics.

Jul 06, 2026 07:00:40

Regeneron Shareholders Approve Key Proposals at Annual Meeting

At the Annual Meeting of Shareholders on June 12, 2026, Regeneron Pharmaceuticals' shareholders elected nominees for Class II directors to serve until the 2027 Annual Meeting. The election results confirmed the leadership continuity within the company.

Additionally, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. An advisory vote on the compensation of the company's named executive officers was also approved, reflecting shareholder support for the current compensation structure.

Jun 17, 2026 16:05:37

Regeneron Reports First Quarter 2026 Financial Performance and Updates

Regeneron Pharmaceuticals reported a 19% increase in revenues for the first quarter of 2026, totaling $3.6 billion compared to the same period in 2025. Key product sales included Dupixent, which saw a 33% rise in global net sales to $4.9 billion, and EYLEA HD, which experienced a 52% increase in U.S. net sales to $468 million. The company also reported GAAP earnings per share of $6.75 and non-GAAP earnings per share of $9.47, both reflecting impacts from research and development expenses. A new $3.0 billion share repurchase program was authorized, alongside a cash dividend of $0.94 per share declared for June 2026.

In terms of product development, Regeneron received multiple FDA approvals, including for Dupixent in young children and EYLEA HD with extended dosing intervals. The company has a robust pipeline with nearly 50 product candidates in clinical development, including advancements in gene therapy and oncology. Additionally, Regeneron announced agreements with the U.S. government aimed at lowering drug prices and entered collaborations to enhance its research capabilities. The company continues to focus on capital allocation strategies that include investing in innovation while returning capital to shareholders.

Apr 29, 2026 06:50:22

Regeneron Projects $102 Million Charge for Q1 2026 Results

Regeneron Pharmaceuticals anticipates an acquired in-process research and development charge of approximately $102 million for the first quarter of 2026. This charge will be reflected in both GAAP and non-GAAP financial results and is expected to reduce net income per diluted share by about $0.81. The charge is associated with equity securities purchased and payments related to collaboration and licensing agreements.

The company's financial results for the first quarter of 2026 are still being finalized and are subject to change. Regeneron emphasizes that the actual results may differ from preliminary estimates and that the acquired IPR&D charges are uncertain in terms of occurrence and timing. Additionally, Regeneron uses non-GAAP financial measures to provide a clearer view of its operating performance, but these measures may not be directly comparable to those of other companies.

Apr 08, 2026 07:05:58

Regeneron Reports 2025 Financial Results and Key Developments

Regeneron Pharmaceuticals announced its financial results for the fourth quarter and full year 2025, showing a 3% increase in fourth quarter revenues to $3.9 billion and a 1% increase in full year revenues to $14.3 billion compared to 2024. Notably, Dupixent's global net sales rose 34% in the fourth quarter to $4.9 billion, while EYLEA HD's U.S. net sales increased by 66% to $506 million in the same period. The company reported a GAAP EPS of $7.86 and a non-GAAP EPS of $11.44 for the fourth quarter, which included a $0.14 impact from an acquired IPR&D charge.

In addition to financial results, Regeneron highlighted several important product approvals and pipeline advancements. EYLEA HD received FDA approval for treating macular edema following retinal vein occlusion, and Dupixent was approved for chronic spontaneous urticaria in Europe. The company is investing approximately $2 billion in a new manufacturing facility in New York, expected to create 1,000 jobs. Regeneron also declared a cash dividend of $0.94 per share, payable on March 5, 2026, to shareholders of record as of February 20, 2026.

Jan 30, 2026 06:51:21

Regeneron Reports Q4 2025 Financial Expectations and Contributions

Regeneron Pharmaceuticals announced preliminary financial information for the fourth quarter and full year 2025 during a corporate update. The company anticipates an acquired in-process research and development charge of approximately $19 million, which is expected to reduce both GAAP and non-GAAP net income per diluted share by about $0.14. This charge includes costs related to asset acquisitions and collaboration agreements, and actual results may vary as they are subject to financial statement closing procedures.

Additionally, Regeneron has committed to a matching program for donations to the Good Days organization, with a total matching contribution of up to $200 million for 2025. In the fourth quarter alone, the company recorded a charge of approximately $60 million related to this program. The preliminary financial results are not finalized and may differ from the estimates provided in the update.

Jan 12, 2026 06:48:25

Regeneron Reports Third Quarter 2025 Financial Results and Updates

Regeneron Pharmaceuticals announced its financial results for the third quarter of 2025, reporting revenues of $3.75 billion, a 1% increase from the same quarter in 2024. Key products included Dupixent, which saw global net sales rise 27% to $4.86 billion, and EYLEA HD, with U.S. net sales increasing 10% to $431 million. The company reported a GAAP EPS of $13.62 and a non-GAAP EPS of $11.83, although the results were impacted by an $80 million charge related to acquired in-process research and development. The company also highlighted the FDA approval of Libtayo as the first immunotherapy for high-risk cutaneous squamous cell carcinoma and positive Phase 3 trial results for several products in its pipeline.

In terms of capital allocation, Regeneron invested nearly $5 billion in R&D and capital expenditures in the first nine months of 2025 and returned over $3 billion to shareholders through share repurchases and dividends. The company resolved patent litigation regarding EYLEA biosimilars, preventing market entry until late 2026. Additionally, Regeneron has approximately 45 product candidates in clinical development, with several regulatory submissions planned for the upcoming quarters, indicating ongoing commitment to innovation and shareholder value.

Oct 28, 2025 06:50:40

Regeneron Reports $83 Million Charge Impacting Q3 2025 Earnings

Regeneron Pharmaceuticals anticipates a financial charge of approximately $83 million for in-process research and development (IPR&D) in its third quarter 2025 results. This charge is primarily due to an $80 million upfront payment made to Hansoh Pharmaceuticals under a licensing agreement. The expected impact on both GAAP and non-GAAP net income per diluted share is about $0.68, which may affect investor sentiment regarding the company's financial performance.

The company notes that the results for the third quarter 2025 are not finalized and are subject to closing procedures. Regeneron emphasizes that actual results may differ from these preliminary estimates. Additionally, the report discusses the use of non-GAAP financial measures, which provide investors with insight into the company's core operating performance but may not be directly comparable to similar measures from other companies.

Oct 06, 2025 07:00:49

Regeneron Reports Second Quarter 2025 Financial Results

Regeneron Pharmaceuticals announced its financial results for the second quarter of 2025, reporting revenues of $3.68 billion, a 4% increase compared to the same period in 2024. Key highlights include a 22% rise in global net sales of Dupixent to $4.34 billion and a 29% increase in U.S. net sales of EYLEA HD to $393 million. The company achieved GAAP earnings per share of $12.81, a 3% increase, while non-GAAP earnings per share rose 12% to $12.89. The FDA granted approval for Lynozyfic for multiple myeloma and additional indications for Dupixent, further enhancing the company's product portfolio.

In addition to its financial performance, Regeneron has made significant investments in manufacturing and returned over $2.3 billion to shareholders through share repurchases and dividends. The company has approximately 45 product candidates in clinical development, including advancements in its oncology portfolio and new indications for existing products. The anticipated regulatory approvals for EYLEA HD are expected to be delayed due to a recent FDA inspection. Regeneron continues to focus on expanding its pipeline and addressing various serious diseases through innovative therapies.

Aug 01, 2025 06:49:57

Regeneron Reports Q1 2025 Results and Pipeline Developments

Regeneron Pharmaceuticals reported first quarter 2025 revenues of $3.0 billion, with a GAAP diluted earnings per share (EPS) of $7.27 and a non-GAAP diluted EPS of $8.22. The company's Dupixent® global net sales rose 19% to $3.67 billion, while EYLEA HD® U.S. net sales increased 54% to $307 million. However, total EYLEA HD and EYLEA U.S. net sales decreased 26% to $1.04 billion. The company received regulatory approvals for Dupixent in chronic spontaneous urticaria in the U.S. and chronic obstructive pulmonary disease in Japan, and the FDA accepted priority review for EYLEA HD's supplemental Biologics License Application for retinal vein occlusion and monthly dosing in approved indications. Additionally, Lynozyfic™ was approved in the EU for multiple myeloma, and regulatory applications for Libtayo® in adjuvant cutaneous squamous cell carcinoma were submitted in the U.S. and EU.

In terms of financial performance, Regeneron's GAAP net income for the first quarter was $809 million, a 12% increase from the prior year, while non-GAAP net income decreased by 17% to $928 million. The company announced ongoing investments in infrastructure and manufacturing in New York and North Carolina, expected to exceed $7 billion. Regeneron also initiated a new share repurchase program, authorizing up to $3 billion, and declared a cash dividend of $0.88 per share, payable in June 2025. The company continues to focus on advancing its clinical pipeline, with 45 product candidates currently in development.

Apr 29, 2025 06:37:44